The consequences of mepolizumab-mediated depletion of eosinophils on adaptive and innate immune responses.

Withdrawn

• Conditions: adaptive and innate defense; immune system; 10001708; 10006436

• Registration Number: NL-OMON45798
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

severe asthma

Exclusion Criteria

anemia, very low white blood cell count, anti-inflammatory and/or immunosuppressive medication other than used to treat asthma

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>genotyping white blood cells<br /><br>humoral parameters and cellular differentiation of mucosal tissue (sputum and<br /><br>nasal lavage)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>